drugset
drugset / Trial / NCT02264054

Pharmacokinetics of Talsaclidine After Administration to Healthy Subjects

NCT02264054 ↗

Phase 1 Completed 6 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to investigate metabolism, pharmacokinetic, safety and tolerability of talsaclidine.

Timeline

Start
1999-02
Primary completion
1999-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Talsaclidine Small molecule 20 mg Oral

Indications

No indication recorded.